These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34486919)

  • 1. Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.
    Riera P; Páez D
    Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1157-1163. PubMed ID: 34486919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2009 Jan; 11(1):15-20. PubMed ID: 19125128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
    Zhu X; Ma R; Ma X; Yang G
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32936306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer.
    Marcuello E; Altés A; Menoyo A; Del Rio E; Gómez-Pardo M; Baiget M
    Br J Cancer; 2004 Aug; 91(4):678-82. PubMed ID: 15280927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.
    Palomaki GE; Bradley LA; Douglas MP; Kolor K; Dotson WD
    Genet Med; 2009 Jan; 11(1):21-34. PubMed ID: 19125129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
    Fujii H; Yamada Y; Watanabe D; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):123-129. PubMed ID: 30377777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
    Riera P; Salazar J; Virgili AC; Tobeña M; Sebio A; Gallano P; Barnadas A; Páez D
    Br J Clin Pharmacol; 2018 Jun; 84(6):1389-1392. PubMed ID: 29504153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics and irinotecan therapy.
    Hahn KK; Wolff JJ; Kolesar JM
    Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
    Liu D; Li J; Gao J; Li Y; Yang R; Shen L
    BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
    Páez D; Tobeña M; Fernández-Plana J; Sebio A; Virgili AC; Cirera L; Barnadas A; Riera P; Sullivan I; Salazar J
    Br J Cancer; 2019 Jan; 120(2):190-195. PubMed ID: 30585257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
    Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
    Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
    Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
    BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan-based chemotherapy in Chinese populations.
    Ma X; Han S; Liu Y; Liu JT; Fang J; Zhang YH
    J Pharm Pharmacol; 2020 Nov; 72(11):1528-1535. PubMed ID: 32737884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
    Tejpar S; Yan P; Piessevaux H; Dietrich D; Brauchli P; Klingbiel D; Fiocca R; Delorenzi M; Bosman F; Roth AD
    Eur J Cancer; 2018 Aug; 99():66-77. PubMed ID: 29909091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of UGT1A1*6, UGT1A1*28, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: Meta-analysis.
    Atasilp C; Biswas M; Jinda P; Nuntharadthanaphong N; Rachanakul J; Hongkaew Y; Vanwong N; Saokaew S; Sukasem C
    Clin Transl Sci; 2022 Jul; 15(7):1613-1633. PubMed ID: 35506159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.
    Roncato R; Cecchin E; Montico M; De Mattia E; Giodini L; Buonadonna A; Solfrini V; Innocenti F; Toffoli G
    Clin Pharmacol Ther; 2017 Jul; 102(1):123-130. PubMed ID: 28074472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
    Wang XF; Ma C; Gong FF; Yi SY; Xing GC; Wang KJ; Yang Q; Cao W
    Zhonghua Zhong Liu Za Zhi; 2018 Aug; 40(8):594-599. PubMed ID: 30139029
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
    Innocenti F; Ratain MJ
    Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
    Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
    Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.
    Hahn RZ; Antunes MV; Verza SG; Perassolo MS; Suyenaga ES; Schwartsmann G; Linden R
    Curr Med Chem; 2019; 26(12):2085-2107. PubMed ID: 29932028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.